Aarti Pharmalabs Ltd
Aarti Pharmalabs Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets around 15% revenue growth in FY'26. FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth.
From Aarti Pharmalabs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets around 15% revenue growth in FY'26.
- CDMO business is expected to grow 30%-40% in FY'26, contributing approximately 15%-16% of total revenue.
- Xanthine business aims for Rs. 1,000 crore to Rs. 1,250 crore in revenue with 80%-90% capacity utilization by FY'29.
- API & Intermediates segment growth driven by regulated markets and new product launches, particularly anti-cancer and anti-diabetic drugs.
- New products and launches expected over next 2-3 years will contribute to growth, strengthening market share.
- Atali plant commercialization expected by FY'26 end, with phased operationalization supporting capacity expansion.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY'25 CAPEX: Around Rs. 400 crores spent.
- FY'26 CAPEX guidance: Rs. 400-450 crores planned.
- Major CAPEX break-up for Rs. 800-850 crores cumulative over FY'25 and FY'26:
- Atali Greenfield project: Rs. 400-425 crores.
- Xanthine capacity expansion: Rs. 150 crores.
- Solar plant: Rs. 85 crores.
- Other smaller projects and R&D: approx. Rs. 40 crores annually.
- Atali project mechanical completion expected by end of current quarter; operational ramp-up phased through FY'26.
- Xanthine capacity expansion (to 9,000 MT) commissioned phased in H2 FY'26, fully operational by Q1 FY'27.
- Solar plant payback expected in about 3.5 to 4 years, with cost savings materializing in FY'26.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Aarti Pharmalabs is currently working with 21 customers in the CDMO/CMO segment.
- The number of active projects has increased to 61 (from 56 last quarter).
- Out of these, 33 projects are at the commercial stage, and 27 are under various development stages at the customer's end.
- Approximately 70-75% of the commercialized projects contributed to revenue in FY'25.
- The company focuses on both primary and secondary supplier roles in these projects and values both for commercial success.
2 more points management made on order book & pipeline
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q4 FY25 results?
The company targets around 15% revenue growth in FY'26. FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
FY'25 CAPEX: Around Rs.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.